Granted Patent
B2
US 12,291,508 · App. 18/244,659 · Granted May 6, 2025
Hydrazide containing nuclear transport modulators and uses thereof
Inventors:
Vincent P. Sandanayaka (Northboro, MA); Sharon Shacham (Newton, MA); Dilara McCauley (Arlington, MA); Sharon Shechter (Andover, MA)
Assignee:
Karyopharm Therapeutics Inc.
C07D249/08A61K31/4196A61K31/4439A61K31/454A61K31/496A61K31/497A61K31/498A61K31/506A61K31/5377A61K31/55C07D241/20C07D401/12C07D403/12C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I. or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Claims (16)
1. A method for treating a disorder associated with CRM1 activity comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the following structural formula:
and a pharmaceutically acceptable carrier.
2. The method according to claim 1 , wherein the disorder is multiple myeloma.
3. The method according to claim 1 , wherein the disorder is a lymphoma.
4. The method according to claim 1 , wherein the method further comprises administering an effective amount of a a second therapeutic agent.
5. The method of claim 1 , wherein the pharmaceutical composition is administered orally.
6. The method according to claim 2 , wherein the method further comprises administering an effective amount of a second therapeutic agent.
7. The method according to claim 2 , wherein the pharmaceutical composition is administered orally.
8. The method according to claim 3 , wherein the method further comprises administering an effective amount of a second therapeutic agent.
9. The method according to claim 3 , wherein the pharmaceutical composition is administered orally.
10. The method according to claim 1 , wherein the disorder is a myelodysplastic syndrome.
11. The method according to claim 10 , wherein the method further comprises administering an effective amount of a second therapeutic agent.
12. The method according to claim 10 , wherein the pharmaceutical composition is administered orally.
13. The method of claim 1 , wherein the disorder is a myeloproliferative disorder.
14. The method according to claim 13 , wherein the method further comprises administering an effective amount of a second therapeutic agent.
15. The method according to claim 13 , wherein the pharmaceutical composition is administered orally.
Assignments (3)
PATENT SECURITY AGREEMENT
Recorded Oct 10, 2025
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL TRUSTEE
Reel/Frame 073058/0504 →
PATENT SECURITY AGREEMENT
Recorded Oct 10, 2025
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT
Reel/Frame 073058/0647 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 21, 2024
From: SANDANAYAKA, VINCENT P.; SHACHAM, SHARON; MCCAULEY, DILARA; SHECHTER, SHARON
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 069360/0626 →
Continuity (13)
Continuation
14235306
Provisional Application
61513428
· Jul 29, 2011
Provisional Application
61513432
· Jul 29, 2011
Provisional Application
61610178
· Mar 13, 2012
Provisional Application
61654651
· Jun 1, 2012
Provisional Application
61653588
· May 31, 2012
References Cited (310)
US 5153201A
· Aono et al.
· 1992
[cited by applicant]
US 5817677A
· Linz et al.
· 1998
[cited by applicant]
US 6462049B1
· Ogura et al.
· 2002
[cited by applicant]
US 7342115B2
· Hutchison et al.
· 2008
[cited by applicant]
US 7667041B2
· Kimura et al.
· 2010
[cited by applicant]
US 7795457B2
· Fu et al.
· 2010
[cited by applicant]
US 7858621B2
· Kim et al.
· 2010
[cited by applicant]
US 7902367B2
· Nomura et al.
· 2011
[cited by applicant]
US 8273738B2
· Osakada et al.
· 2012
[cited by applicant]
US 8299102B2
· Strobel et al.
· 2012
[cited by applicant]
US 8304438B2
· Strobel et al.
· 2012
[cited by applicant]
US 8513230B2
· Shacham et al.
· 2013
[cited by applicant]
US 8598168B2
· Moradei et al.
· 2013
[cited by applicant]
US 8999996B2
· Sandanayaka et al.
· 2015
[cited by applicant]
US 9079865B2
· Sandanayaka et al.
· 2015
[cited by applicant]
US 9096543B2
· Sandanayaka et al.
· 2015
[cited by applicant]
US 9206158B2
· Sandanayaka et al.
· 2015
[cited by applicant]
US 9266843B2
· Sandanayaka et al.
· 2016
[cited by applicant]
US 9303000B2
· Sandanayaka et al.
· 2016
[cited by applicant]
US 9428490B2
· Sandanayaka et al.
· 2016
[cited by applicant]
US 9550757B2
· Shacham et al.
· 2017
[cited by applicant]
US 9585874B2
· Sandanayaka et al.
· 2017
[cited by applicant]
US 9714226B2
· Sandanayaka et al.
· 2017
[cited by applicant]
US 9738624B2
· Baloglu et al.
· 2017
[cited by applicant]
US 9828373B2
· Liu et al.
· 2017
[cited by applicant]
US 9861614B2
· Sandanayaka et al.
· 2018
[cited by applicant]
US 20020025539A1
· Dellinger et al.
· 2002
[cited by applicant]
US 20030018025A1
· Thurkauf et al.
· 2003
[cited by applicant]
US 20040092598A1
· Watkins et al.
· 2004
[cited by applicant]
US 20060004069A1
· Momose et al.
· 2006
[cited by applicant]
US 20090221586A1
· Okada et al.
· 2009
[cited by applicant]
US 20090298896A1
· Sakuma et al.
· 2009
[cited by applicant]
US 20100016272A1
· Strobel et al.
· 2010
[cited by applicant]
US 20100056569A1
· Nan et al.
· 2010
[cited by applicant]
US 20110009374A1
· Keller
· 2011
[cited by applicant]
US 20110275607A1
· Shacham et al.
· 2011
[cited by applicant]
US 20120258986A1
· Sandanayaka et al.
· 2012
[cited by applicant]
US 20130317031A1
· Sandanayaka et al.
· 2013
[cited by applicant]
US 20140155370A1
· Shacham et al.
· 2014
[cited by applicant]
US 20140235653A1
· Sandanayaka et al.
· 2014
[cited by applicant]
US 20140364408A1
· Sandanayaka et al.
· 2014
[cited by applicant]
US 20150018332A1
· Sandanayaka et al.
· 2015
[cited by applicant]
US 20150111893A1
· Sandanayaka et al.
· 2015
[cited by applicant]
US 20150274698A1
· Sandanayaka et al.
· 2015
[cited by applicant]
US 20160145246A1
· Sandanayaka et al.
· 2016
[cited by applicant]
US 20160152596A1
· Baloglu et al.
· 2016
[cited by applicant]
US 20160258931A1
· Silva et al.
· 2016
[cited by applicant]
US 20160304500A1
· Rashal et al.
· 2016
[cited by applicant]
US 20170137430A1
· Sandanayaka et al.
· 2017
[cited by applicant]
US 20170319551A1
· Sandanayaka et al.
· 2017
[cited by applicant]
US 20180155317A1
· Baloglu et al.
· 2018
[cited by applicant]
US 20190016690A1
· Baloglu
· 2019
[cited by applicant]
US 20190023693A1
· Chennuru et al.
· 2019
[cited by applicant]
US 20190160063A1
· Baloglu
· 2019
[cited by applicant]
US 20200087313A1
· Sandanayaka et al.
· 2020
[cited by applicant]
US 20200199099A1
· Baloglu et al.
· 2020
[cited by applicant]
US 20200283419A1
· Austad et al.
· 2020
[cited by applicant]
US 20200339521A1
· Sandanayaka et al.
· 2020
[cited by applicant]
US 20220056038A1
· Sandanayaka et al.
· 2022
[cited by applicant]
US 20220073478A1
· Sandanayaka et al.
· 2022
[cited by applicant]
US 20220135545A1
· Austad et al.
· 2022
[cited by applicant]
US 20220177445A1
· Baloglu et al.
· 2022
[cited by applicant]
US 20230242516A1
· Austad et al.
· 2023
[cited by applicant]
US 20230242517A1
· Austad et al.
· 2023
[cited by applicant]
US 20230391754A1
· Wiedemann et al.
· 2023
[cited by applicant]
CN 101309912A
· 2008
[cited by applicant]
CN 101466687A
· 2009
[cited by applicant]
CN 103002742A
· 2013
[cited by applicant]
CN 103874690B
· 2016
[cited by applicant]
EP 0069513A2
· 1983
[cited by applicant]
EP 1939180A1
· 2008
[cited by applicant]
EP 1992618A1
· 2008
[cited by applicant]
EP 2003118A1
· 2008
[cited by applicant]
EP 2090570A1
· 2009
[cited by applicant]
EP 2736887A1
· 2014
[cited by applicant]
EP 3808742A1
· 2021
[cited by applicant]
JP S5841875A
· 1983
[cited by applicant]
JP S62103065A
· 1987
[cited by applicant]
JP H04211089A
· 1992
[cited by applicant]
JP H07118237A
· 1995
[cited by applicant]
JP H11263764A
· 1999
[cited by applicant]
JP 2003342262A
· 2003
[cited by applicant]
JP 2004509941A
· 2004
[cited by applicant]
JP 2004168768A
· 2004
[cited by applicant]
JP 2005508905A
· 2005
[cited by applicant]
JP 2005255683A
· 2005
[cited by applicant]
JP 2006504761A
· 2006
[cited by applicant]
JP 2007210929A
· 2007
[cited by applicant]
JP 2009203238A
· 2009
[cited by applicant]
JP 2009536615A
· 2009
[cited by applicant]
JP 2009544696A
· 2009
[cited by applicant]
JP 2010513341A
· 2010
[cited by applicant]
JP 2010519337A
· 2010
[cited by applicant]
JP 2015516434A
· 2015
[cited by applicant]
JP 2018012715A
· 2018
[cited by applicant]
KR 20050062645A
· 2005
[cited by applicant]
WO WO199616040A1
· 1996
[cited by applicant]
WO WO199715567A1
· 1997
[cited by applicant]
WO WO199737996A1
· 1997
[cited by applicant]
WO WO199748696A1
· 1997
[cited by applicant]
WO WO199825893A1
· 1998
[cited by applicant]
WO WO199950264A1
· 1999
[cited by applicant]
WO WO200162756A1
· 2001
[cited by applicant]
WO WO200226696A1
· 2002
[cited by applicant]
WO WO2003024448A2
· 2003
[cited by applicant]
WO WO2004039365A1
· 2004
[cited by applicant]
WO WO2004039764A1
· 2004
[cited by applicant]
WO WO2004043925A2
· 2004
[cited by applicant]
WO WO2004043951A1
· 2004
[cited by applicant]
WO WO2004076418A1
· 2004
[cited by applicant]
WO WO2005115990A1
· 2005
[cited by applicant]
WO WO2006016637A1
· 2006
[cited by applicant]
WO WO2006019020A1
· 2006
[cited by applicant]
WO WO2006088246A1
· 2006
[cited by applicant]
WO WO2007102580A1
· 2007
[cited by applicant]
WO WO2007147336A1
· 2007
[cited by applicant]
WO WO2008029825A1
· 2008
[cited by applicant]
WO WO2008074413A2
· 2008
[cited by applicant]
WO WO2008152097A1
· 2008
[cited by applicant]
WO WO2010017545A2
· 2010
[cited by applicant]
WO WO2011069039A1
· 2011
[cited by applicant]
WO WO2011109799A1
· 2011
[cited by applicant]
WO WO2012099807A1
· 2012
[cited by applicant]
WO WO2013019548A1
· 2013
[cited by applicant]
WO WO2013019561A1
· 2013
[cited by applicant]
WO WO2013020024A2
· 2013
[cited by applicant]
WO WO2013170068A2
· 2013
[cited by applicant]
WO WO2014144772A1
· 2014
[cited by applicant]
WO WO2014152263A1
· 2014
[cited by applicant]
WO WO2014205389A1
· 2014
[cited by applicant]
WO WO2014205393A1
· 2014
[cited by applicant]
WO WO2016025904A1
· 2016
[cited by applicant]
WO WO2017117529A1
· 2017
[cited by applicant]
WO WO2017117535A1
· 2017
[cited by applicant]
WO WO2017118940A1
· 2017
[cited by applicant]
WO WO2018098472A1
· 2018
[cited by applicant]
WO WO2018129227A1
· 2018
[cited by applicant]
WO WO2022087218A1
· 2022
[cited by applicant]
Abarbri et al., “Efficient synthesis of conjugated (2E)-or (2Z)-n-4-ynoic acids and (2E, 4E)-or (2Z, 4E)-dienoic acids via palladium-catalysed cross coupling”, Synthesis 1996, issue 1, pp. 82-86.
[cited by applicant]
Balbach et al., Pharmaceutical evaluation of early development candidates: “The 100 mg- approach,” International Journal of Pharmaceutics, 275:1-12 (2004).
[cited by applicant]
Balsamini, “(E)-3-(2-(N-Phenylcarbamoyl)vinyl)pyrrole-2-carboxylic Acid Derivatives. A Novel Class of Glycine Site Antagonists”, Journal of Medicinal Chemistry, 41(6):808-820 (1998).
[cited by applicant]
Brekhov, Y. et al., “Cyanomethyltetrazoles II reactions of the methylene Fragment”, Zhurnal organicheskoi Khimii, 28(9): 1921-1925 (1992).
[cited by applicant]
Brittain, “Drugs in Pharmaceutical Sciences, v. 192. Polymorphism in Pharmaceutical Solids,” CRC Press (2009).
[cited by applicant]
Bryn et al., “Pharmaceutical Solids: A Strategic Approach To Regulatory Considerations,” Pharma Res 12(7):945-954 (1995).
[cited by applicant]
Buckler, R.T. et al., “Synthesis and Antiinflammatory Activity of Some 1,2,3- and 1,2,4-Triazolepropionic Acids”, Journal of Medicinal Chemistry, 21(12): 1254-1260 (1978).
[cited by applicant]
Burdeska et al., “Anil-Synthese. 23. Mitteilung. Ueber die Herstellung von Styryl- und Stilbenyl-Derivaten des Pyrimidins // Anil synthesis. Part 23. Preparation of styryl and stilbenyl derivatives of pyrimidines,” Helv…
[cited by applicant]
Cai, X., et al., “Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage”, Proc Nat Acad Sci, 105(44):16958-16963 (2008).
[cited by applicant]
Caira, M.R., “Crystalline polymorphism of organic compounds”. In: Weber, E., et al. Design of Organic Solids. Topics in Current Chemistry, vol. 198. pp. 163-208 (1998).
[cited by applicant]
Cancer [online], [retrieved on Jun. 6, 2007] Retrieved from the Internet, URL: http://www.nlm.nih.gov/medlineplus/cancer.html (Year: 2007).
[cited by applicant]
Cantu et al., “Using the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-350 to Reduce Cortical Circuit Hyperexcitability and Interneuron Cell Loss in the Controlled Cortical Impact (CCI) Model of Traumatic Br…
[cited by applicant]
CAS Registry No. 1000508-38-2 [online], Jan. 23, 2008, 1 page.
[cited by applicant]
CAS Registry No. 151446-45-6 [online] Nov. 25, 1993.
[cited by applicant]
CAS Registry No. 940775-13-3 (Jul. 2, 2007), 1 page.
[cited by applicant]
CAS Registry Nos. 1181485-58-4; 1100108-00-6 (2009).
[cited by applicant]
Chemcats RN# 1035122-02-1; Publicly available on Jul. 12, 2009.
[cited by applicant]
Chemcats RN# 1134927-58-4; Publicly available on Apr. 15, 2009.
[cited by applicant]
Chemcats RN# 930886-49-0; Publicly available on Apr. 29, 2007.
[cited by applicant]
Cheng et al., “XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer,” Mol Cancer Ther 13(3):675-686 (2014).
[cited by applicant]
Cooper et al., “Synthesis of Some 1,2,4-Triazoles and 1,2,4-Triazolines by Reaction of Oxamidrazone Condensation Products with Acetic Anhydride,” Journal of Chemical Society Perkin Transactions I, 15: 1433-1437 (1975).
[cited by applicant]
Cronshaw, J.M. et al., “The nuclear pore complex: disease associations and functional correlations”, Trends Endocrin Metab. 15(1):34-39 (2004).
[cited by applicant]
Daelemans, D. et al., “A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export”, PNAS, 99(22):14440-14445 (2002).
[cited by applicant]
Davis, J.R. et al., “Controlling protein compartmentalization to overcome disease” Pharmaceut Res., 24(1):17-27 (2007).
[cited by applicant]
Dorwald, “Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design,” Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim (2005).
[cited by applicant]
Etchin et al., “KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia,” British Journal …
[cited by applicant]
Extended European Search Report for EP Application No. 17189480.1 dated May 16, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 22176543.1 dated Oct. 12, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 23162715.9 dated Aug. 9, 2023.
[cited by applicant]
Extended European Search Report for EP Application No. EP 18202641 mailed Feb. 15, 2019.
[cited by applicant]
Extended European Search Report issued by the European Patent Office in corresponding European Application No. 18164757.0 issued Aug. 8, 2018.
[cited by applicant]
Extended Search Report for EP Application No. 11751491.9, “Nuclear Transport Modulators and Uses Thereof”, Date of Completion of the Search: Dec. 17, 2013. 6 pages.
[cited by applicant]
Extended Search Report for EP Application No. 12736172.3, “Olefin Containing Nuclear Transport Modulators and Uses Thereof”, Date of Completion of the Search: May 8, 2014. 3 pages.
[cited by applicant]
Falini, B. et al., “Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML”, Blood, 107(11):4514-4523 (2013).
[cited by applicant]
Freundt, E.C. et al., “Molecular Determinants for Subcellular Localization of the Severe Acute Respiratory Syndrome Coronavirus Open Reading Frame 3b Protein”, Journal of Virology, 83(13):6631-6640 (2009).
[cited by applicant]
Ghildyal, R. et al., “The Respiratory Syncytial Virus Matrix Protein Possesses a Crm1-Mediated Nuclear Export Mechanism”, Journal of Virology, 83(11):5353-5362 (2009).
[cited by applicant]
Ghosh, C.C. et al., “Analysis of nucleocytoplasmic shuttling of NF kappa B proteins in human leukocytes”, Methods Mol. Biol. 457:279-92 (2008).
[cited by applicant]
Gilmore C.J. X-ray diffraction. In: Storey R.A., Ymén I., editors. Solid state characterization of pharmaceuticals. Chichester: Blackwell Publishing; p. 35-70 (2011).
[cited by applicant]
Golub, T.R. et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, 286: 531-537 (1999).
[cited by applicant]
Gravina et al., “XPO1/CRM1-Selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa),” Journal of Hematology & Oncology, 7(46): (201…
[cited by applicant]
Gupta, N. et al., “Retinal tau pathology in human glaucomas” Can J Ophthalmol. 43(1):53-60 (2008).
[cited by applicant]
Haines et al., “Selective Inhibitors of Nuclear Export Avert Progression in Preclinical Models of Inflammatory Demyelination,” Nature Neuroscience, 18(4): 511-520 (2015).
[cited by applicant]
Hilliard et al., “The anti-inflammatory prostaglandin 15-Deoxy-Δ12, 14 PGJ2 inhibits CRM1-dependent nuclear protein export,” Journal of Biological Chemistry, 285(29): 22202-22210 (2010).
[cited by applicant]
Hoffman et al., “Synthesis of Vinyl-Functionalized Oxazoles by Olefin Cross-Metathesis”, J. Org. Chem. 73: 2400-2403 (2008).
[cited by applicant]
Hoshino, I. et al., “Combined effects of p53 gene therapy and leptomycin B in human esophageal squamous cell carcinoma”, Oncology, 75:113-119 (2008).
[cited by applicant]
Huff, J., “HIV Protease: A Novel Chemotherapeutic Target for AIDS”, Journal of Medicinal Chemistry, 34(8): 2305-2314 (1991).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2011/027328, “Nuclear Transport Modulators and Uses Thereof” dated Sep. 11, 2012.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/021406, “Olefin Containing Nuclear Transport Modulators and Uses Thereof” dated Jul. 17, 2013.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2014/029322 dated Sep. 15, 2015.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2014/043479, dated Dec. 22, 2015.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2014/043484, dated Dec. 22, 2015.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2015/045395 mailed Feb. 21, 2017.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/069492 issued Jul. 3, 2018.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/069508 issued Jul. 3, 2018.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/063439 mailed May 28, 2019.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/048319, “Hydrazide Containing Nuclear Transport Modulators and Uses Thereof”; Date of Issuance of the Report: Feb. 4, 2014.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/048368, Nuclear Transport “Modulators and Uses Thereof”; Date of Issuance of the Report: Feb. 4, 2014.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/040404, “Nuclear Transport Modulators and Uses Thereof”; Date of Issuance of the Report: Nov. 11, 2014.
[cited by applicant]
International Search Report and The Written Opinion of the International Searching Authority for International Application No. PCT/US2012/021406, “Olefin-Containing Nuclear Transport Modulators and Uses Thereof” dated A…
[cited by applicant]
International Search Report and The Written Opinion of the International Searching Authority for International Application No. PCT/US2012/049470, “Maleimide Compounds and Methods of Treatment,” dated Feb. 13, 2013.
[cited by applicant]
International Search Report and The Written Opinion of the International Searching Authority for International Application No. PCT/US2013/040404, “Nuclear Transport Modulators and Uses Thereof”; Date of Mailing: Nov. 18…
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2014/027136 “Exo Olefin-Containing Nuclear Transport Modulators an…
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2014/029322 “Methods of Promoting Wound Healing Using CRM1 Inhibit…
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2014/043479 “Nuclear Transport Modulators and Uses Thereof”; Date …
[cited by applicant]
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2014/043484 “Nuclear Transport Modulators and Uses Thereof”; Date …
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2015/045395 mailed Jan. 12, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/069492 mailed Feb. 16, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/069508 mailed May 23, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/063439 mailed Feb. 2, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/055974 mailed Jan. 4, 2022.
[cited by applicant]
International Search Report for International Application No. PCT/US2011/027328, “Nuclear Transport Modulators And Uses Thereof” dated Apr. 29, 2011.
[cited by applicant]
International Search Report for International Application No. PCT/US2012/048319, “Hydrazide Containing Nuclear Transport Modulators and Uses Thereof” date of mailing: Nov. 9, 2012.
[cited by applicant]
International Search Report for International Application No. PCT/US2012/048368, “Nuclear Transport Modulators and Uses Thereof” date of mailing Sep. 21, 2012.
[cited by applicant]
Jiang et al., “Palladium-Catalyzed Alkenylation of 1,2,3-Trizoles with Terminal Conjugated Alkenes by Direct C—H Bond Functionalization,” Eur J Org Chem, 7:1227-30 (2010).
[cited by applicant]
Karyagin, A. Yu., “Reagents for addressed modification of biopolymers 11. The synthesis of N Im-2,4-dinitrophenyl derivatives of histidine and urocanic and imidazolylacetic acids for anchoring imidazole residues to olig…
[cited by applicant]
Karyopharm Therapeutics, “Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury,” Apr. 20, 2016, Retrieved from the Intern…
[cited by applicant]
Kau, T.R. et al., “A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells”, Cancer Cell, pp. 4(6): 463-476 (2003).
[cited by applicant]
Kaur et al., “Tyrphostin Induced Growth Inhibition: Correlation with Effect on p210bcr-abl Autokinase Activity in K562 Chronic Myelogenous Leukemia,” Anti-Cancer Drugs, 5(2): 213-222 (1994).
[cited by applicant]
Ke, S.-Y. et al., “Research Advance of Acylhydrazine Derivatives with Biological Activities”, Chinese Journal of Organic Chemistry 30(12):1820-1830 (2010).
[cited by applicant]
Lain, S. et al., “Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function”, Exp Cell Res. 253: 315-324 (1999).
[cited by applicant]
Lain, S. et al., “An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs”, Exp Cell Res. 248:457-472 (1999).
[cited by applicant]
Lala, P.K. et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors”, Cancer and Metastasis Reviews, 17: 91-106 (1998).
[cited by applicant]
Lapalombella, R. et al., “Selective Inhibitors of nuclear exports show that CRM1/XPO1 is a target in chronic lymphocytic leukemia”, Blood, 120(23): 4621-4634 (2012).
[cited by applicant]
Li, A. et al., “Upregulation of CRM1 Relates to Neuronal Apoptosis after Traumatic Brain Injury in Adult Rats”, J Mol Neurosci, 51(1):208-218 (2013).
[cited by applicant]
Maekawa et al., “Efficient Formation of a Triazole Ring via Novel Ring-Opening Reaction of (z)-2-Methyl-4-arylmethylene-5(4H)-Oxazolones with Hydrazides,” Heterocycles, 75(12):2959-2971 (2008).
[cited by applicant]
Maga et al., “Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid …
[cited by applicant]
Marelli et al., “Tumor targeting via integrin ligands,” Frontiers in Oncology, 3(222):1-12 (2013).
[cited by applicant]
Miskolci et al., “TNFα release from peripheral blood leukocytes depends on a CRM1-mediated nuclear export,” Biochemical and Biophysical Research Communications, 351:354-360 (2006).
[cited by applicant]
Modzelewska-Banachiewicz, B. et al., “Synthesis and biological activity of (Z) and (E) isomers of 3-(3,4-diaryl-1,2,4-triazole-5-yl)prop-2-enoic acid” Monatsh Chem., 140:439-444 (2009).
[cited by applicant]
Modzelewska-Banachiewicz, B. et al., “Synthesis and biological activity of new derivatives of 3-(3,4-diaryl-1,2,4-triazole-5-yl)propenoic acid” European Journal of Medicinal Chemistry, 39:873-877 (2004).
[cited by applicant]
Monecke, T. et al., “Crystal Structure of the Nuclear Export Receptor CRM1 in Complex with Snurportin1 and RanGTP”, Science, 324:1087-1091 (2009).
[cited by applicant]
Morales et al., Mechanical Particle-Size Reduction Techniques. In: Williams III, R., Watts, A., Miller, D. (eds) Formulating Poorly Water Soluble Drugs. AAPS Advances in the Pharmaceutical Sciences Series, vol. 3. Sprin…
[cited by applicant]
Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Adv Drug Deliv Rev, 56(3):275-300 (2004).
[cited by applicant]
Muller, P.A.J. et al., “Nuclear-Cytosolic Transport of COMMD1 Regulates NF-κB and HIF-1 Activity”, Traffic, 10:514-527 (2009).
[cited by applicant]
Mutka et al., “Identification of Nuclear Export Inhibitors with Potent Anticancer Activity in Vivo,” Cancer Research, 69(2): 510-517 (2009).
[cited by applicant]
Mutka, S. et al., “Nuclear export inhibitors (NEIs) as novel cancer therapeutics”, 98th AACr Ann. Mtg., 2 pgs (Apr. 14-18, 2007) (Poster).
[cited by applicant]
Nagase, The Practice of Medicinal Chemistry, Chapter 13. Conversion of Molecules Based on Equivalent Substitution, vol. 1, Technomics Inc., 1998, 253.
[cited by applicant]
Nair, V., “Thermally induced skeletal rearrangement in a triazepine,” J Heterocyclic Chem, 12(1):183-4 (1975).
[cited by applicant]
Nakahara, J. et al., “Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis”, Journal of Clinical Investigation, 119(1):169-181 (2009).
[cited by applicant]
Nautiyal et al., “Distinct functions for RIP140 in development, inflammation, and metabolism,” Trends in Endocrinology and Metabolism, 24(9):451-459 (2013).
[cited by applicant]
Noske, A., et al., “Expression of the Nuclear Export Protein Chromosomal Region Maintenance/Exportin 1/Xpo1 is a Prognostic Factor in Human Ovarian Cancer”, Cancer, 112(8):1733-1743 (2008).
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/203,181 mailed Oct. 3, 2019.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/891,044 “Nuclear Transport Modulators and Uses Thereof”, dated Apr. 7, 2015.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/931,372 “Nuclear Transport Modulators and Uses Thereof”, dated Sep. 7, 2016.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/235,342 “Nuclear Transport Modulators and Uses Thereof”, dated Apr. 25, 2016.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/735,853 “Nuclear Transport Modulators and Uses Thereof”, dated Aug. 4, 2015.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/747,394 “Nuclear Transport Modulators and Uses Thereof”, dated Aug. 30, 2017.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/900,469 “Nuclear Transport Modulators and Uses Thereof”, dated Apr. 18, 2017.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/940,310 “Hydrazide Containing Nuclear Transport Modulators and Uses Thereof”, dated Mar. 14, 2017.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 14/989,377 “Nuclear Transport Modulators and Uses Thereof”, dated Oct. 28, 2016.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/413,889 “Nuclear Transport Modulators and Uses Thereof”, dated Apr. 10, 2018.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/629,307, Hydrazide Containing Nuclear Transport Modulators and Uses Thereof dated Aug. 29, 2008.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/651,856, “Nuclear Transport Modulators and Uses Thereof” dated Apr. 24, 2019.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/037,798 “Nuclear Transport Modulators and Uses Thereof,” dated Nov. 8, 2019.
[cited by applicant]
Orsted et al., “Basic principles of wound healing,” Wound Care Canada, 9(2): 4-12 (2011).
[cited by applicant]
Patani, G.A., et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem Rev, 96:3147-3176 (1996).
[cited by applicant]
Procopiou et al., “Inhibitors of Cholesterol Biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors,” J Med Chem, 36(23): 3658-3662 (1993).
[cited by applicant]
PubChem Compound, Database Accession No. 33777540 (May 29, 2009), 3 pages.
[cited by applicant]
PubChem Compound, Database Accession No. 33777561 (May 29, 2009), 3 pages.
[cited by applicant]
PubChem Compound, Database Accession No. 33777585 (May 29, 2009), 3 pages.
[cited by applicant]
PubChem Compound, Database Accession No. 66525271 (Oct. 24, 2012), 3 pages.
[cited by applicant]
PubChem Compound, Database Accession No. 66525276 (Oct. 24. 2012), 3 pages.
[cited by applicant]
PubChem Compound, Database Accession No. 72062355 (Dec. 2, 2007), 11 pages.
[cited by applicant]
Quan, M.L. et al., “Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors”, J. Med. Chem. 42: 2760-2773 (1999).
[cited by applicant]
Rawlinson, S.M. et al., “CRM1-mediated Nuclear Export of Dengue Virus RNA Polymerase NS5 Modulates Interleukin-8 Induction and Virus Production”, Journal of Biological Chemistry, 284(23):15589-15597 (2009).
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 13/041,377 “Nuclear Transport Modulators and Uses Thereof”, dated Jul. 5, 2012.
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 13/350,864 “Olefin Containing Nuclear Transport Modulators and Uses Thereof”, dated Dec. 19, 2013.
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 13/931,372 “Nuclear Transport Modulators and Uses Thereof”, dated May 22, 2014.
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 14/235,342 “Nuclear Transport Modulators and Uses Thereof”, dated Jun. 9, 2015.
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 14/777,302 “Methods of Promoting Wound Healing Using CRM1 Inhibitors”, dated Sep. 22, 2016.
[cited by applicant]
Requirement for Restriction/Election for U.S. Appl. No. 15/217,514 “Nuclear Transport Modulators and Uses Thereof”, dated Aug. 8, 2017.
[cited by applicant]
Sakamoto et al., “Studies on Pyrimidine Derivatives. XXV. Reaction of Pyrimidinyl Aldehydes and Ketones with Wittig Reagents,” Chem Pharm Bull, 30(2): 610-614 (1982).
[cited by applicant]
Sanchez, V. et al., “Nuclear Export of the Human Cytomegalovirus Tegument Protein pp65 Requires Cyclin-Dependent Kinase Activity and the Crm1 Exporter”, Journal of Virology, 81(21):11730-11736 (2007).
[cited by applicant]
Shasheva, “Reactions of Hydroxyphenyl-Substituted 1,2,4-Triazoles with Electrophilic Reagents”, Russian Journal of General Chemistry, 79(10): 2234-2243 (2009).
[cited by applicant]
Singhal et al., “Drug Polymorphism and Dosage Form Design: A practical perspective,” Advanced Drug Delivery Reviews, 56:335-347 (2004).
[cited by applicant]
Sorokin, A.V. et al., “Nucleocytoplasmic Transport of Proteins”, Biochemistry Moscow, 72(13):1439-1457 (2007).
[cited by applicant]
Sun et al., “Inhibiting cancer cell hallmark features through nuclear export inhibition.” Signal Transduction and Targeted Therapy 1.1 (2016): 1-10.
[cited by applicant]
Sun Q., et al., “Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1”, Proc Nat Acad Sci, 110(4): 1303-1308 (2013).
[cited by applicant]
Tai et al., “CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications,” Leukemia, 28:155-165 (2014).
[cited by applicant]
Tamir et al., “KPT-350, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Efficacy in the Mouse Pilocapine Model of Temporal Lobe Epilepsy,” Journal of Neurological Sciences, 381 (Suppl): 87-88 (2017).
[cited by applicant]
Terry, L.J. et al., “Crossing the Nuclear Envelope: Hierarchical Regulation of Nucleocytoplasmic Transport”, Science, 318:1412-1416 (2007).
[cited by applicant]
Tominaga et al., “Studies on Positive Inotropic Agents. I. Synthesis of 3,4-Dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone and Related Compounds”, Chem. Pharm. Bull. 32(6): 2100-2110 (1984).
[cited by applicant]
Van der Watt, P.J. et al., “The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation”, Int. J. Cancer, 124:1829-1840 (2009).
[cited by applicant]
Van Neck et al., “Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure-activity relationship and mechanism of action”, Bioorganic & Medicinal Chemistry 16:9487-9497 (2008).
[cited by applicant]
Walsh, Jr., M.D., et al., “Exportin 1 Inhibition Attenuates Nuclear Factor-κB-Dependent Gene Expression”, Shock, 29(2):160-166 (2008).
[cited by applicant]
Wang et al., “Mathematical modeling in cancer drug discovery,” Drug Discovery Today, 19(2):145-150 (2014).
[cited by applicant]
Williams, P., et al., “Characterization of a CRM1-Dependent Nuclear Export Signal in the C Terminus of Herpes Simplex Virus Type 1 Tegument Protein UL47”, Journal of Virology, 82(21):10946-10952 (2008).
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2011/027328, “Nuclear Transport Modulators and Uses Thereof” dated Apr. 29, 2011, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2012/048319, “Hydrazide Containing Nuclear Transport Modulators and Uses Thereof” dated Nov. 9, 2012, 9 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2012/048368, “Nuclear Transport Modulators and Uses Thereof” dated Sep. 21, 2012, 11 pages.
[cited by applicant]
Wu et al., Application of temperature cycling for crystal quality control during crystallization, CrystEngComm, 18(13): 2222-2238 (2016).
[cited by applicant]
Yao, Y., et al., “The expression of CRM1 is associated with prognosis in human osteosarcoma”, Oncology Reports, 21:229-235 (2009).
[cited by applicant]
Yonemochi, “Physicochemical Properties for Amorphous Pharmaceuticals and their Stability,” Cryobiol and Cryotechnol 51(1):25-30 (2005).
[cited by applicant]
Zheng et al., “KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma,” Cancer Chemother Pharmacol, 74:487-495 (2014).
[cited by applicant]
Zimmerman, T.L. et al., “Nuclear Export of Retinoid X Receptor alpha in Response to Interleukin-1beta-mediated Cell Signaling Roles for JNK and Ser260”, Journal of Biological Chemistry, 281(22):15434-15440 (2006).
[cited by applicant]
Cited By (3)